Log in to search using one of your social media accounts:

 

Intrathecal injection of scAAV9-hIGF1 prolongs the survival of ALS model mice by inhibiting the NF-kB pathway

Publication date: Available online 12 February 2018 Source:Neuroscience Author(s): HaoJie Hu, HuiQian Lin, WeiSong Duan, Can Cui, ZhongYao Li, YaKun Liu, Wan Wang, Di Wen, Ying Wang, ChunYan Li Amyotrophic lateral sclerosis (ALS) is a chronic, fatal neurodegenerative disorder characterized by the progressive loss of upper and lower motor neurons. Currently, there is no effective drug for ALS. Recent studies in ALS model mice have shown that insulin-like growth factor-1 (IGF1) may be a promising therapeutic drug. We demonstrate that self-complementary adeno-associated virus serum type 9 encoding the human IGF1 (scAAV9-hIGF1) could significantly postpone the onset and slow down the progression of the disease owning to inhibiting the NF-κB signalling pathway. Furthermore, the results were supported by experiments in which the CRISPR/Cas9 system was used to knock-down IGF1 in ALS mice (mIGF1). Our data indicate that IGF1-mediated suppression of NF-κB activation in microglia is novel molecular mechanism underlying MN death in ALS. It provides new insight of IGF1 and points towards novel therapeutic target of IGF1 in ALS. Graphical abstract
Source: Neuroscience - Category: Neuroscience Source Type: research

Related Links:

In conclusion, the present study demonstrated that TIGIT is a prominent negative immune regulator involved in immunosenescence. This novel finding is highly significant, as targeting TIGIT might be an effective strategy to improve the immune response and decrease age-related comorbidities. Delivery of Extracellular Vesicles as a Potential Basis for Therapies https://www.fightaging.org/archives/2018/01/delivery-of-extracellular-vesicles-as-a-potential-basis-for-therapies/ Here I'll point out a readable open access review paper on the potential use of extracellular vesicles as a basis for therapy: harveste...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Publication date: 4 December 2017 Source:Neuroscience, Volume 365 Author(s): Dongxiao Li, Chong Liu, Chunxing Yang, Dan Wang, Dongxia Wu, Yinkuang Qi, Qin Su, Guangping Gao, Zuoshang Xu, Yansu Guo Mutant SOD1 causes amyotrophic lateral sclerosis (ALS) by a dominant gain of toxicity. Previous studies have demonstrated therapeutic potential of mutant SOD1-RNAi delivered by intrathecal (IT) injection of recombinant adeno-associated virus (rAAV). However, optimization of delivery is needed to overcome the high degree of variation in the transduction efficiency and therapeutic efficacy. Here, on the basis of our previously def...
Source: Neuroscience - Category: Neuroscience Source Type: research
Our research is devoted to the identification of efficient strategies to target the central nervous system (CNS) and to the development of novel therapies for motor neuron disorders. In particular, using the unique therapeutic potential of self-complementary adeno-associated virus (AAV) vectors, we recently elaborated a new gene therapy strategy for a genetic form of Amyotrophic Lateral Sclerosis (ALS), a lethal disease with limited therapeutic options. Approximately 20% of familial ALS cases are caused by mutations in the Superoxide Dismutase 1 (SOD1) gene and toxic gain of function of the mutant protein.
Source: Neuromuscular Disorders - Category: Neurology Authors: Source Type: research
Publication date: Available online 24 August 2017 Source:Neuroscience Research Author(s): Kuniyuki Endo, Shinsuke Ishigaki, Yoshito Masamizu, Yusuke Fujioka, Akiya Watakabe, Tetsuo Yamamori, Nobuhiko Hatanaka, Atsushi Nambu, Haruo Okado, Masahisa Katsuno, Hirohisa Watanabe, Masanori Matsuzaki, Gen Sobue Fused in sarcoma (FUS) is an RNA binding protein that is involved in frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). To establish the common marmoset (Callithrix jacchus) as a model for FTLD, we generated a stereotaxic injection-based marmoset model of FUS-silencing. We designed shRNAs aga...
Source: Neuroscience Research - Category: Neuroscience Source Type: research
ABSTRACT Intronic GGGGCC repeat expansions in C9orf72 are the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Two major pathologies stemming from the hexanucleotide RNA expansions (HREs) have been identified in postmortem tissue: intracellular RNA foci and repeat-associated non-ATG dependent (RAN) dipeptides, although it is unclear how these and other hallmarks of disease contribute to the pathophysiology of neuronal injury. Here, we describe two novel lines of mice that overexpress either 10 pure or 102 interrupted GGGGCC repeats mediated by adeno-associated virus (AAV) ...
Source: DMM Disease Models and Mechanisms - Category: Biomedical Science Authors: Tags: Neurodegenerative disorders RESEARCH ARTICLE Source Type: research
by Tomohiro Ishii, Emiko Kawakami, Kentaro Endo, Hidemi Misawa, Kazuhiko Watabe TAR DNA-binding protein 43 (TDP-43) is a main constituent of cytoplasmic aggregates in neuronal and glial cells in cases of amyotrophic lateral sclerosis and frontotemporal lobar degeneration. We have previously demonstrated that adenovirus-transduced artificial TDP-43 cytoplasmic aggregates forma tion is enhanced by proteasome inhibitionin vitro andin vivo. However, the relationship between cytoplasmic aggregate formation and cell death remains unclear. In the present study, rat neural stem cell lines stably transfected with EGFP- or Sirius-e...
Source: PLoS One - Category: Biomedical Science Authors: Source Type: research
Conclusions:Identification of the mechanisms of neuronal differential vulnerability may lead to development of new therapeutic strategies that prevent the progressive neurodegeneration in MN diseases.Study Supported by: Cariplo Foundation to SC (2012-0513), Thierry Latran Foundation to SC and EH, JPND; 529-2014-7500 to SC and EH; ARISLA to SC.Disclosure: Dr. Nizzardo has nothing to disclose. Dr. Rizzo has nothing to disclose. Dr. Taiana has nothing to disclose. Dr. Allodi has nothing to disclose. Dr. Aguila Benitez has nothing to disclose. Dr. Nijssen has nothing to disclose. Dr. Ulzi has nothing to disclose. Dr. Melzi has...
Source: Neurology - Category: Neurology Authors: Tags: Neuromuscular and Clinical Neurophysiology (EMG): Motor Neuron Disease I Source Type: research
In this study, we proved that AAV9 vector mediated expression of human wild-type IGF-1 protected TDP-25 cells from apoptosis and oxidative stress. Furthermore, we demonstrated that the hIGF-1 exerted its neuroprotective effect through an Akt-dependent manner in cultured motoneurons. We also described a hypothesis that in cultured TDP-25-associated degeneration of motoneurons, the neuronal survival promotion of IGF-1 was related to VEGF.
Source: Neuroscience Letters - Category: Neuroscience Source Type: research
Abstract Monoclonal antibodies (mAbs) based-therapies are currently one of the most successful strategies to treat immune disorders, cancer and infectious diseases. Vectors derived from adeno-associated virus (AAV) are very attractive to deliver the genes coding the mAbs because they allow long-term expression thus, reducing the number of administrations. They can also penetrate biological barriers such as the blood-brain-barrier to transduce cells localized in immunoprivileged organs. Recent animal studies with AAV have demonstrated the capacity of AAV to deliver sufficient quantity of antibodies to confer an eff...
Source: Current Gene Therapy - Category: Genetics & Stem Cells Authors: Tags: Curr Gene Ther Source Type: research
In conclusion, administering ssAAV9-DAO may be an effective complementary approach to gene therapy to extend lifespans in symptomatic ALS. PMID: 28025800 [PubMed - as supplied by publisher]
Source: Neurochemical Research - Category: Neuroscience Authors: Tags: Neurochem Res Source Type: research
More News: Adenoviruses | ALS | Brain | Insulin | Neurology | Neuroscience | Study